We are live on ! Find out more
MC

Mayo Clinic Portfolio holdings

AUM $2.9M
1-Year Est. Return 14.49%
This Fund
S&P 500
This Quarter Est. Return
-19.96%
1 Year Est. Return
+14.49%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.03M
AUM Growth
-$3.12M
Cap. Flow
-$862K
Cap. Flow %
-28.46%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
1
Avg Time Held
13 quarters
Top 10 Avg Time Held
9.3 quarters
Top 20 Avg Time Held
9.3 quarters

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$862K

Sector Composition

Rank Sector Weight
1 Miscellaneous 64.41%
2 Healthcare 35.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ACWI icon
1
iShares MSCI ACWI ETF
ACWI
$33.2B
$1.95M 64.41%
17,359
– –
2022 Q4
6 quarters
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$239M
$765K 25.27%
187,143
– –
2020 Q2
16 quarters
UBX icon
3
DELISTED
Unity Biotechnology
UBX
$168K 5.53%
124,081
– –
2019 Q4
18 quarters
NMTC icon
4
NeuroOne Medical Technologies
NMTC
$9.79M
$145K 4.8%
30,292
– –
2021 Q2
12 quarters
CATX icon
5
Perspective Therapeutics
CATX
$288M
– –
-72,464
Closed -$862K –

Similar funds

Mayo Clinic's Q2 2024 Portfolio in Review

As of Q2 2024, Mayo Clinic held 5 positions worth $3.03M, down 51% from $6.15M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Mayo Clinic withdrew a net $862K in Q2 2024, closing 1 position. Its most notable exit was Perspective Therapeutics, an estimated $862K position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 64% of assets, up from 31% a quarter earlier, followed by Healthcare.

  • Mayo Clinic fully exited Perspective Therapeutics in Q2 2024, selling an estimated $862K.
  • Mayo Clinic's ten largest holdings make up 100% of its $3.03M portfolio in Q2 2024.
  • Mayo Clinic opened 0 new positions and closed 1 in Q2 2024.
  • Mayo Clinic's portfolio value fell 51% quarter-over-quarter to $3.03M.

Based on Mayo Clinic's 13F filing for Q2 2024, filed 12 Aug 2024.